Rebecca A Hubbard, Ph.D.
University of Pennsylvania School of Medicine
604 Blockley Hall
423 Guardian Drive
Philadelphia, PA 19104
B.S. (Ecology & Evolution, summa cum laude)
University of Pittsburgh, Pittsburgh, PA, 1999.
University of Edinburgh, Edinburgh, UK, 2001.
M.Sc. (Applied Statistics, with honors)
Oxford University, Oxford, UK, 2002.
University of Washington, Seattle, WA , 2007.
Description of Research ExpertiseDr. Hubbard's research focuses on development and application of statistical methodology for studies using observational data from community medical practice. This work encompasses evaluation of screening and diagnostic test performance, methods for comparative effectiveness studies, and health services research. A wealth of data on healthcare utilization, performance, and outcomes are available from electronic medical records. However, the complex observation scheme giving rise to these data necessitates careful study design and analysis to ensure that inference is valid. Dr. Hubbard’s methodological research emphasizes development of statistical tools for such inference and has been applied to studies of cancer screening, aging and dementia, pharmacoepidemiology, women’s health, and behavioral health.
Selected PublicationsTong J, Huang J, Chubak J, Wang X, Hubbard RA, Chen Y: An augmented estimation procedure for EHR-based association studies accounting for differential misclassification. Journal of the American Medical Informatics Association 27(2): 244-253, February 2020.
Upshaw JN, Finkelman B, Hubbard RA, Smith AM, Narayan H, Arndt L, Domchek S, DeMichele A, Fox K, Shah P, Clark A, Bradbury A, Matro J, Adusumalli S, Carver JR, Ky B: Comprehensive assessment of changes in left ventricular diastolic function with contemporary breast cancer therapy. Journal of the American College of Cardiology: Cardiovascular Imaging 13(1): 198-210, January 2020.
Demissei BG, Hubbard RA, Zhang L, Smith AM, Sheline K, McDonald C, Narayan V, Domchek SM, DeMichele A, Shah P, Clark AS, Fox K, Matro J, Bradbury A, Knollman H, Getz K, Armenian S, Januzzi J, Tang WH, Liu P, Ky B: Changes in cardiovascular biomarkers with breast cancer therapy and associations with cardiac dysfunction. Journal of the American Heart Association 9: e014708, January 2020.
Bittermann T, Hubbard RA, Goldberg D: The proportion of Model for End-stage Liver Disease Sodium score attributable to creatinine independently predicts post-transplant survival and renal complications. Clinical Transplantation In press, 2020.
Kenyon CC, Maltenfort MG, Hubbard RA, Schinazi L, de Roos A, Henrickson S, Forrest CB: Variability in diagnosed asthma in young children in a large pediatric primary care network. Academic Pediatrics In press, 2020.
Neighborhood-level measures of socioeconomic status are more correlated with individual-level measures in urban areas compared to less urban areas: Xie S, Hubbard RA*, Himes BE* Annals of Epidemiology In press, 2020 Notes: *Equal contribution.
Chen L, Chubak J, Yu O, Pocobelli GP, Ziebell RA, Bowles EA, Fujii MM, Sterrett AT, Boggs JM, Ritzwoller DP, Hubbard RA, Boudreau DM: Changes in use of opioid therapy after colon cancer diagnosis: a population-based study. Cancer Causes & Control 30(12): 1341-1350, December 2019.
Bittermann T, Hubbard RA, Lewis JD, Goldberg DS: The use of induction therapy in liver transplantation is highly variable and is associated with post-transplant outcomes. American Journal of Transplantation 19(12): 3319-3327, December 2019.
Ibáñez-Sanz G, Garcia M, Milà N, Hubbard RA, Vidal C, Binefa G, Benito L, Moreno V on behalf of the ‘Adverse Effects on Colorectal Cancer Screening in Catalonia (EACC) Study’ working group: False-positive results in a population-based colorectal screening programme: cumulative risk over seven biennial FOBT screening rounds. Cancer Epidemiology, Biomarkers & Prevention 28(11): 1909-1916, November 2019.
Feld E, Harton J, Meropol NJ, Adamson B, Cohen A, Parikh RB, Galsky MD, Narayan VK, Christodouleas J, Vaughn D, Hubbard RA*, Mamtani R*: Effectiveness of first-line immune checkpoint blockade versus carboplatin-based chemotherapy for metastatic urothelial cancer. European Urology 76(4): 524-532, October 2019 Notes: *Equal contribution.